GT Biopharma
GTBP
57 hedge funds and large institutions have $12.9M invested in GT Biopharma in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 28 reducing their positions, and 7 closing their positions.
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
16% more call options, than puts
Call options by funds: $156K | Put options by funds: $135K
8% more funds holding
Funds holding: 53 → 57 (+4)
0.11% less ownership
Funds ownership: 0.6% → 0.49% (-0.11%)
23% less capital invested
Capital invested by funds: $16.7M → $12.9M (-$3.83M)
82% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$151K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$105K |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$75.8K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$62.9K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$57.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$642K |
| 2 |
Two Sigma Investments
New York
|
-$549K |
| 3 |
Morgan Stanley
New York
|
-$517K |
| 4 |
Renaissance Technologies
New York
|
-$354K |
| 5 |
Two Sigma Advisers
New York
|
-$298K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCS
51
Gordian Capital (Singapore)
Singapore
| $3K | – | – | – |
|
52
Citigroup
New York
| $2K | -$11.6K | -131 | -86% |
|
|
TF
53
TimeScale Financial
Danvers,
Massachusetts
| $2K | – | – | – |
|
|
BBPWM
54
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $1K | – | – | – |
|
|
APA
55
American Portfolios Advisors
Holbrook,
New York
| $40 | – | – | – |
|
|
56
Two Sigma Investments
New York
| – | -$549K | -6,003 | Closed |
|
|
AFM
57
Anson Funds Management
Dallas,
Texas
| – | -$133K | -1,456 | Closed |
|
58
D.E. Shaw & Co
New York
| – | -$129K | -1,413 | Closed |
|
59
Ameriprise
Minneapolis,
Minnesota
| – | -$44K | -486 | Closed |
|
60
Squarepoint
New York
| – | -$33K | -359 | Closed |
|
61
Optiver Holding
Amsterdam,
Netherlands
| – | -$17K | -86 | Closed |
|
|
IAG
62
Investmark Advisory Group
Shelton,
Connecticut
| – | -$4K | -48 | Closed |
|
|
EI
63
Ellevest Inc
New York
| – | -$176 | -2 | -67% |
|
|
CAL
64
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$88 | +1 | New |
|
GTBP Hedge Fund Activity: Q1 2022 in Review
57 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q1 2022, worth a combined $12.9M — down 23% from $16.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new GTBP positions and 7 closed out — a net gain of 4 holders — while 5 added to existing stakes and 28 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $151K. The largest seller was Vanguard Group, cutting an estimated $642K.
- 57 institutional investors held GT Biopharma (GTBP) as of Q1 2022, up from 53 in Q4 2021.
- Funds reported $12.9M of GT Biopharma stock for Q1 2022, down 23% quarter-over-quarter.
- 11 funds opened new GT Biopharma positions in Q1 2022 and 7 closed out, a net change of +4 holders.
- The largest GT Biopharma buyer in Q1 2022 was Fidelity Investments, an estimated $151K added.
- The largest GT Biopharma seller in Q1 2022 was Vanguard Group, an estimated $642K sold.
Based on aggregated 13F filings for Q1 2022.